 Edwin deZoeten
Concepts (331)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Inflammatory Bowel Diseases | 15 | 2023 | 320 | 4.030 |
Why?
| | T-Lymphocytes, Regulatory | 14 | 2023 | 375 | 3.440 |
Why?
| | Colitis | 12 | 2021 | 242 | 3.180 |
Why?
| | Crohn Disease | 8 | 2023 | 217 | 1.680 |
Why?
| | HSP90 Heat-Shock Proteins | 3 | 2014 | 45 | 1.190 |
Why?
| | Forkhead Transcription Factors | 9 | 2023 | 185 | 1.180 |
Why?
| | Ileitis | 3 | 2017 | 33 | 1.090 |
Why?
| | Inflammation | 9 | 2023 | 2736 | 1.060 |
Why?
| | CD4-Positive T-Lymphocytes | 5 | 2018 | 1056 | 0.890 |
Why?
| | Immunity, Mucosal | 2 | 2023 | 94 | 0.850 |
Why?
| | Immune System Diseases | 1 | 2023 | 34 | 0.820 |
Why?
| | Gastroenterologists | 1 | 2023 | 18 | 0.820 |
Why?
| | Diarrhea | 2 | 2017 | 180 | 0.810 |
Why?
| | Biosimilar Pharmaceuticals | 1 | 2023 | 20 | 0.810 |
Why?
| | Adenosine Triphosphatases | 2 | 2014 | 161 | 0.800 |
Why?
| | Colitis, Ulcerative | 1 | 2023 | 119 | 0.750 |
Why?
| | Clostridium Infections | 2 | 2022 | 64 | 0.730 |
Why?
| | Eosinophilia | 4 | 2019 | 204 | 0.720 |
Why?
| | Colon | 4 | 2018 | 254 | 0.660 |
Why?
| | Fecal Microbiota Transplantation | 2 | 2022 | 21 | 0.620 |
Why?
| | Enteral Nutrition | 1 | 2020 | 188 | 0.620 |
Why?
| | Systems Biology | 1 | 2019 | 59 | 0.610 |
Why?
| | CCAAT-Enhancer-Binding Protein-beta | 1 | 2018 | 32 | 0.610 |
Why?
| | Colonic Diseases | 1 | 2018 | 32 | 0.580 |
Why?
| | Lactoferrin | 1 | 2017 | 28 | 0.560 |
Why?
| | DNA, Neoplasm | 4 | 2002 | 159 | 0.550 |
Why?
| | Histone Deacetylases | 5 | 2012 | 212 | 0.490 |
Why?
| | Cytoplasm | 3 | 2013 | 263 | 0.480 |
Why?
| | Intestinal Mucosa | 7 | 2018 | 590 | 0.480 |
Why?
| | Precision Medicine | 1 | 2019 | 387 | 0.480 |
Why?
| | Mice | 26 | 2023 | 16937 | 0.470 |
Why?
| | Mice, Inbred C57BL | 19 | 2018 | 5440 | 0.460 |
Why?
| | Novobiocin | 1 | 2014 | 5 | 0.450 |
Why?
| | Tumor Necrosis Factor-alpha | 4 | 2022 | 1198 | 0.440 |
Why?
| | Melanoma, Experimental | 5 | 2002 | 108 | 0.440 |
Why?
| | Anus Diseases | 1 | 2013 | 7 | 0.430 |
Why?
| | Mice, Knockout | 10 | 2023 | 2871 | 0.430 |
Why?
| | Fistula | 1 | 2013 | 35 | 0.420 |
Why?
| | Cell Nucleus | 2 | 2014 | 582 | 0.420 |
Why?
| | Phenotype | 3 | 2019 | 3076 | 0.410 |
Why?
| | Enzyme Inhibitors | 2 | 2014 | 827 | 0.410 |
Why?
| | Abscess | 1 | 2013 | 73 | 0.410 |
Why?
| | Anal Canal | 1 | 2013 | 88 | 0.410 |
Why?
| | Infliximab | 4 | 2023 | 100 | 0.360 |
Why?
| | Animals | 28 | 2023 | 35361 | 0.340 |
Why?
| | Fibroblasts | 6 | 2002 | 948 | 0.340 |
Why?
| | Cancer Vaccines | 4 | 2001 | 164 | 0.330 |
Why?
| | Adoptive Transfer | 3 | 2014 | 218 | 0.330 |
Why?
| | Heat Shock Transcription Factors | 2 | 2023 | 19 | 0.320 |
Why?
| | Dextran Sulfate | 3 | 2014 | 78 | 0.320 |
Why?
| | Interleukin-2 | 6 | 2019 | 436 | 0.310 |
Why?
| | Proprotein Convertases | 1 | 2008 | 15 | 0.310 |
Why?
| | Sucrase-Isomaltase Complex | 1 | 2008 | 1 | 0.310 |
Why?
| | Carbohydrate Metabolism, Inborn Errors | 1 | 2008 | 2 | 0.310 |
Why?
| | Biological Therapy | 1 | 2008 | 28 | 0.300 |
Why?
| | Lymphocyte Activation | 3 | 2014 | 1106 | 0.300 |
Why?
| | Biomarkers | 1 | 2019 | 3973 | 0.290 |
Why?
| | Child | 10 | 2023 | 20883 | 0.280 |
Why?
| | Histone Deacetylase Inhibitors | 4 | 2011 | 209 | 0.280 |
Why?
| | Interleukin-10 | 4 | 2018 | 304 | 0.270 |
Why?
| | Humans | 34 | 2023 | 129650 | 0.270 |
Why?
| | Biomedical Research | 1 | 2013 | 638 | 0.270 |
Why?
| | Research Design | 1 | 2013 | 1044 | 0.270 |
Why?
| | Repressor Proteins | 1 | 2009 | 406 | 0.260 |
Why?
| | CTLA-4 Antigen | 2 | 2021 | 87 | 0.250 |
Why?
| | Transfection | 5 | 2002 | 911 | 0.250 |
Why?
| | DNA-Binding Proteins | 1 | 2013 | 1443 | 0.240 |
Why?
| | Remission Induction | 2 | 2020 | 272 | 0.240 |
Why?
| | Flow Cytometry | 5 | 2017 | 1156 | 0.240 |
Why?
| | Immunotherapy, Adoptive | 1 | 2008 | 295 | 0.230 |
Why?
| | Transcription Factors | 1 | 2013 | 1651 | 0.230 |
Why?
| | Mice, Transgenic | 4 | 2023 | 2119 | 0.230 |
Why?
| | H-2 Antigens | 3 | 2001 | 115 | 0.230 |
Why?
| | Autoimmune Diseases | 1 | 2008 | 426 | 0.230 |
Why?
| | Cell Proliferation | 6 | 2019 | 2391 | 0.210 |
Why?
| | Genetic Therapy | 3 | 2002 | 292 | 0.210 |
Why?
| | Heat-Shock Response | 1 | 2023 | 72 | 0.210 |
Why?
| | Adalimumab | 1 | 2023 | 39 | 0.210 |
Why?
| | Ileum | 3 | 2023 | 116 | 0.200 |
Why?
| | Cytokines | 5 | 2018 | 2017 | 0.200 |
Why?
| | Abdominal Abscess | 1 | 2022 | 26 | 0.200 |
Why?
| | Age of Onset | 1 | 2023 | 496 | 0.190 |
Why?
| | Retrospective Studies | 7 | 2022 | 14518 | 0.190 |
Why?
| | Vaccines, DNA | 2 | 1999 | 28 | 0.190 |
Why?
| | Histocompatibility Antigens Class I | 2 | 2002 | 200 | 0.190 |
Why?
| | Intestines | 2 | 2023 | 348 | 0.190 |
Why?
| | Blotting, Western | 4 | 2015 | 1205 | 0.180 |
Why?
| | Haploinsufficiency | 1 | 2021 | 48 | 0.180 |
Why?
| | Practice Guidelines as Topic | 1 | 2008 | 1501 | 0.170 |
Why?
| | Pediatrics | 1 | 2008 | 1052 | 0.170 |
Why?
| | Graft vs Host Disease | 1 | 2022 | 241 | 0.170 |
Why?
| | Neoplasms, Experimental | 1 | 2001 | 171 | 0.170 |
Why?
| | Diagnosis, Differential | 2 | 2018 | 1434 | 0.160 |
Why?
| | Infant | 4 | 2020 | 9024 | 0.160 |
Why?
| | Interleukin-2 Receptor beta Subunit | 1 | 2019 | 18 | 0.160 |
Why?
| | Celiac Disease | 1 | 2022 | 286 | 0.160 |
Why?
| | Mammary Neoplasms, Experimental | 1 | 1999 | 66 | 0.160 |
Why?
| | Feces | 2 | 2022 | 440 | 0.150 |
Why?
| | Integrins | 1 | 2019 | 94 | 0.150 |
Why?
| | Real-Time Polymerase Chain Reaction | 2 | 2017 | 331 | 0.150 |
Why?
| | Recurrence | 2 | 2022 | 1007 | 0.150 |
Why?
| | Immunotherapy | 2 | 2002 | 592 | 0.150 |
Why?
| | Colonoscopy | 2 | 2017 | 236 | 0.150 |
Why?
| | Disease Progression | 2 | 2019 | 2635 | 0.140 |
Why?
| | Receptor, Cannabinoid, CB2 | 1 | 2017 | 10 | 0.140 |
Why?
| | Fibrosis | 2 | 2023 | 520 | 0.140 |
Why?
| | Parents | 2 | 2020 | 1309 | 0.140 |
Why?
| | Th17 Cells | 1 | 2018 | 83 | 0.140 |
Why?
| | Th1 Cells | 1 | 2018 | 138 | 0.140 |
Why?
| | Immunoglobulin A | 2 | 2022 | 200 | 0.140 |
Why?
| | Cells, Cultured | 4 | 2018 | 4083 | 0.140 |
Why?
| | Stomach | 1 | 2017 | 109 | 0.140 |
Why?
| | Intubation, Gastrointestinal | 1 | 2017 | 77 | 0.140 |
Why?
| | Attitude to Health | 1 | 2020 | 431 | 0.140 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2022 | 573 | 0.140 |
Why?
| | Gene Deletion | 1 | 2018 | 379 | 0.140 |
Why?
| | Antibodies, Monoclonal | 3 | 2013 | 1367 | 0.140 |
Why?
| | Jurkat Cells | 2 | 2014 | 134 | 0.130 |
Why?
| | Killer Cells, Natural | 2 | 2019 | 427 | 0.130 |
Why?
| | Gastrostomy | 1 | 2017 | 111 | 0.130 |
Why?
| | Chronic Disease | 4 | 2022 | 1720 | 0.130 |
Why?
| | Gene Expression Regulation | 4 | 2014 | 2548 | 0.130 |
Why?
| | Disease Models, Animal | 5 | 2018 | 4063 | 0.130 |
Why?
| | Adrenal Cortex Hormones | 1 | 2019 | 522 | 0.120 |
Why?
| | Mice, Inbred C3H | 5 | 2007 | 273 | 0.120 |
Why?
| | Signal Transduction | 3 | 2019 | 4925 | 0.120 |
Why?
| | Interleukin-33 | 1 | 2015 | 48 | 0.120 |
Why?
| | Molecular Sequence Data | 2 | 2011 | 2832 | 0.120 |
Why?
| | Genetic Predisposition to Disease | 1 | 2023 | 2282 | 0.120 |
Why?
| | Receptor, Adenosine A2B | 1 | 2015 | 44 | 0.120 |
Why?
| | Fatty Acids, Omega-6 | 1 | 2015 | 47 | 0.120 |
Why?
| | Marijuana Use | 1 | 2018 | 192 | 0.120 |
Why?
| | Marijuana Smoking | 1 | 2018 | 247 | 0.110 |
Why?
| | Ikaros Transcription Factor | 1 | 2014 | 23 | 0.110 |
Why?
| | Recombinant Proteins | 1 | 2017 | 1304 | 0.110 |
Why?
| | NFATC Transcription Factors | 1 | 2014 | 84 | 0.110 |
Why?
| | Genomics | 1 | 2019 | 716 | 0.110 |
Why?
| | Infant, Newborn | 2 | 2023 | 5762 | 0.110 |
Why?
| | Tumor Necrosis Factor Ligand Superfamily Member 13 | 1 | 2013 | 3 | 0.110 |
Why?
| | Transmembrane Activator and CAML Interactor Protein | 1 | 2013 | 3 | 0.110 |
Why?
| | Pruritus Ani | 1 | 2013 | 2 | 0.110 |
Why?
| | Suppuration | 1 | 2013 | 9 | 0.110 |
Why?
| | Fissure in Ano | 1 | 2013 | 3 | 0.110 |
Why?
| | Enterocolitis | 1 | 2013 | 17 | 0.110 |
Why?
| | Transcription Factor RelA | 1 | 2014 | 81 | 0.110 |
Why?
| | Motivation | 1 | 2018 | 546 | 0.110 |
Why?
| | Hydroxamic Acids | 2 | 2011 | 88 | 0.110 |
Why?
| | Plasma Cells | 1 | 2013 | 67 | 0.100 |
Why?
| | Adolescent | 5 | 2018 | 20393 | 0.100 |
Why?
| | T-Lymphocytes | 2 | 2019 | 1928 | 0.100 |
Why?
| | Female | 12 | 2018 | 68776 | 0.100 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2019 | 759 | 0.100 |
Why?
| | Leukocyte Common Antigens | 1 | 2013 | 82 | 0.100 |
Why?
| | Interleukin-12 Subunit p40 | 1 | 2012 | 9 | 0.100 |
Why?
| | Lactams, Macrocyclic | 1 | 2013 | 49 | 0.100 |
Why?
| | Benzoquinones | 1 | 2013 | 48 | 0.100 |
Why?
| | Fecal Incontinence | 1 | 2013 | 80 | 0.100 |
Why?
| | Immunosuppressive Agents | 1 | 2017 | 853 | 0.100 |
Why?
| | Enzyme Activation | 1 | 2014 | 811 | 0.100 |
Why?
| | alpha 1-Antitrypsin | 1 | 2013 | 107 | 0.100 |
Why?
| | Glutathione Transferase | 1 | 2012 | 101 | 0.100 |
Why?
| | MicroRNAs | 1 | 2018 | 678 | 0.100 |
Why?
| | Wet Macular Degeneration | 1 | 2012 | 46 | 0.090 |
Why?
| | Histone Deacetylase 6 | 1 | 2011 | 17 | 0.090 |
Why?
| | Protein Transport | 1 | 2013 | 428 | 0.090 |
Why?
| | Consent Forms | 1 | 2011 | 12 | 0.090 |
Why?
| | Heart Transplantation | 1 | 2017 | 721 | 0.090 |
Why?
| | Transplantation Tolerance | 1 | 2011 | 35 | 0.090 |
Why?
| | Gene Targeting | 1 | 2011 | 82 | 0.090 |
Why?
| | Microarray Analysis | 1 | 2011 | 122 | 0.090 |
Why?
| | Computers | 1 | 2011 | 65 | 0.090 |
Why?
| | Immunoprecipitation | 1 | 2011 | 157 | 0.090 |
Why?
| | Anilides | 1 | 2011 | 73 | 0.090 |
Why?
| | Mice, Inbred BALB C | 2 | 2011 | 1245 | 0.090 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2012 | 958 | 0.090 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2012 | 274 | 0.090 |
Why?
| | Consensus | 1 | 2013 | 616 | 0.090 |
Why?
| | Autoimmunity | 2 | 2019 | 862 | 0.090 |
Why?
| | Treatment Outcome | 3 | 2022 | 10230 | 0.080 |
Why?
| | Male | 10 | 2018 | 63681 | 0.080 |
Why?
| | Epigenesis, Genetic | 2 | 2012 | 613 | 0.080 |
Why?
| | Informed Consent | 1 | 2011 | 170 | 0.080 |
Why?
| | Tumor Cells, Cultured | 3 | 2001 | 940 | 0.080 |
Why?
| | HSP70 Heat-Shock Proteins | 1 | 2009 | 69 | 0.080 |
Why?
| | Hemorrhage | 1 | 2013 | 678 | 0.080 |
Why?
| | Epitopes | 2 | 2002 | 470 | 0.080 |
Why?
| | Epithelial Cells | 1 | 2015 | 1065 | 0.080 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2008 | 82 | 0.080 |
Why?
| | Retroviridae | 1 | 2008 | 99 | 0.080 |
Why?
| | Oxazolone | 1 | 2008 | 5 | 0.080 |
Why?
| | Picrates | 1 | 2008 | 5 | 0.080 |
Why?
| | RNA, Messenger | 3 | 2013 | 2708 | 0.080 |
Why?
| | Homeostasis | 1 | 2012 | 611 | 0.080 |
Why?
| | Trinitrobenzenesulfonic Acid | 1 | 2008 | 9 | 0.080 |
Why?
| | Growth | 1 | 2008 | 58 | 0.070 |
Why?
| | Antigens, Neoplasm | 3 | 2001 | 309 | 0.070 |
Why?
| | Endoscopy | 1 | 2011 | 285 | 0.070 |
Why?
| | Bystander Effect | 1 | 2008 | 15 | 0.070 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2008 | 372 | 0.070 |
Why?
| | Mutation | 1 | 2019 | 3717 | 0.070 |
Why?
| | Indoles | 1 | 2011 | 387 | 0.070 |
Why?
| | Polymerase Chain Reaction | 1 | 2011 | 1038 | 0.070 |
Why?
| | Child, Preschool | 3 | 2017 | 10517 | 0.070 |
Why?
| | Pediatric Obesity | 1 | 2015 | 572 | 0.070 |
Why?
| | Transplantation Immunology | 1 | 2007 | 34 | 0.070 |
Why?
| | Immunologic Factors | 1 | 2009 | 231 | 0.070 |
Why?
| | Cohort Studies | 1 | 2017 | 5420 | 0.070 |
Why?
| | Pain | 1 | 2013 | 789 | 0.070 |
Why?
| | Graft Rejection | 1 | 2011 | 598 | 0.070 |
Why?
| | DNA Methylation | 1 | 2012 | 607 | 0.070 |
Why?
| | Immunization | 2 | 2001 | 411 | 0.070 |
Why?
| | Cell Line | 3 | 2002 | 2781 | 0.070 |
Why?
| | Cell Survival | 1 | 2009 | 1086 | 0.060 |
Why?
| | Antigens, CD | 1 | 2008 | 489 | 0.060 |
Why?
| | Recombinant Fusion Proteins | 1 | 2008 | 643 | 0.060 |
Why?
| | Hypoxia | 1 | 2012 | 1084 | 0.060 |
Why?
| | Chromatin | 1 | 2008 | 479 | 0.060 |
Why?
| | Homeodomain Proteins | 1 | 2008 | 495 | 0.060 |
Why?
| | Anti-Inflammatory Agents | 1 | 2008 | 480 | 0.060 |
Why?
| | Amino Acid Sequence | 1 | 2008 | 2058 | 0.060 |
Why?
| | Macrophages | 1 | 2012 | 1480 | 0.060 |
Why?
| | Aged | 1 | 2023 | 22103 | 0.060 |
Why?
| | Evidence-Based Medicine | 1 | 2008 | 718 | 0.060 |
Why?
| | Transplantation, Homologous | 2 | 2022 | 401 | 0.060 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2008 | 704 | 0.050 |
Why?
| | Cell Movement | 1 | 2008 | 945 | 0.050 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2008 | 1368 | 0.050 |
Why?
| | Duodenum | 1 | 2022 | 75 | 0.050 |
Why?
| | Cellulitis | 1 | 2022 | 48 | 0.050 |
Why?
| | Transglutaminases | 1 | 2022 | 153 | 0.050 |
Why?
| | Necrosis | 1 | 2022 | 232 | 0.050 |
Why?
| | Acute Disease | 2 | 2015 | 980 | 0.050 |
Why?
| | Promoter Regions, Genetic | 2 | 2018 | 1207 | 0.050 |
Why?
| | Age Factors | 1 | 2008 | 3144 | 0.040 |
Why?
| | Mice, Inbred DBA | 1 | 2001 | 188 | 0.040 |
Why?
| | T-Lymphocytes, Cytotoxic | 2 | 1998 | 169 | 0.040 |
Why?
| | Cell Differentiation | 1 | 2007 | 1902 | 0.040 |
Why?
| | Cell Transplantation | 1 | 1999 | 37 | 0.040 |
Why?
| | Cell Compartmentation | 1 | 2019 | 52 | 0.040 |
Why?
| | Survival Analysis | 2 | 1999 | 1274 | 0.040 |
Why?
| | Interleukin-15 | 1 | 2019 | 82 | 0.040 |
Why?
| | Carboxylic Ester Hydrolases | 1 | 2018 | 20 | 0.040 |
Why?
| | Homozygote | 1 | 2019 | 193 | 0.040 |
Why?
| | Siblings | 1 | 2019 | 215 | 0.040 |
Why?
| | Gastritis | 1 | 2019 | 96 | 0.040 |
Why?
| | Enteritis | 1 | 2019 | 93 | 0.040 |
Why?
| | Immunophenotyping | 1 | 2019 | 311 | 0.040 |
Why?
| | Time Factors | 1 | 2008 | 6556 | 0.030 |
Why?
| | Vaccines, Synthetic | 1 | 1998 | 126 | 0.030 |
Why?
| | Cell Division | 1 | 1999 | 797 | 0.030 |
Why?
| | Cytomegalovirus Infections | 1 | 2019 | 189 | 0.030 |
Why?
| | Gastrointestinal Agents | 1 | 2017 | 61 | 0.030 |
Why?
| | Quality of Life | 1 | 2008 | 2704 | 0.030 |
Why?
| | Epitopes, T-Lymphocyte | 1 | 1998 | 186 | 0.030 |
Why?
| | Decision Making | 1 | 2023 | 851 | 0.030 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 1999 | 857 | 0.030 |
Why?
| | Protein Processing, Post-Translational | 1 | 2018 | 455 | 0.030 |
Why?
| | Patient Acceptance of Health Care | 1 | 2022 | 759 | 0.030 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2001 | 626 | 0.030 |
Why?
| | Glioma | 1 | 1999 | 354 | 0.030 |
Why?
| | In Situ Nick-End Labeling | 1 | 2015 | 124 | 0.030 |
Why?
| | Peroxidase | 1 | 2015 | 174 | 0.030 |
Why?
| | Fibronectins | 1 | 2015 | 123 | 0.030 |
Why?
| | Constriction, Pathologic | 1 | 2015 | 228 | 0.030 |
Why?
| | NF-kappa B | 1 | 2018 | 653 | 0.030 |
Why?
| | Autoantibodies | 1 | 2022 | 1466 | 0.030 |
Why?
| | Interleukin-13 | 1 | 2015 | 147 | 0.030 |
Why?
| | Chemokines | 1 | 2015 | 226 | 0.030 |
Why?
| | Cell Adhesion Molecules | 1 | 2015 | 173 | 0.030 |
Why?
| | Fluorescent Antibody Technique | 1 | 2015 | 376 | 0.030 |
Why?
| | Models, Molecular | 1 | 2019 | 1492 | 0.030 |
Why?
| | B-Cell Maturation Antigen | 1 | 2013 | 9 | 0.030 |
Why?
| | Immunoglobulin Class Switching | 1 | 2013 | 19 | 0.030 |
Why?
| | T-Lymphocytes, Helper-Inducer | 1 | 2014 | 135 | 0.030 |
Why?
| | Self Report | 1 | 2018 | 799 | 0.030 |
Why?
| | Cell Membrane Permeability | 1 | 2013 | 81 | 0.030 |
Why?
| | Cytidine Deaminase | 1 | 2013 | 57 | 0.030 |
Why?
| | Collagen | 1 | 2015 | 434 | 0.030 |
Why?
| | Eosinophils | 1 | 2015 | 324 | 0.030 |
Why?
| | Cell Count | 1 | 2013 | 314 | 0.030 |
Why?
| | Surveys and Questionnaires | 2 | 2018 | 5406 | 0.020 |
Why?
| | Inflammation Mediators | 1 | 2015 | 505 | 0.020 |
Why?
| | Fluorescent Antibody Technique, Indirect | 1 | 2012 | 48 | 0.020 |
Why?
| | Hospitalization | 1 | 2022 | 2070 | 0.020 |
Why?
| | Adenocarcinoma | 1 | 1999 | 898 | 0.020 |
Why?
| | Immunoglobulin M | 1 | 2013 | 275 | 0.020 |
Why?
| | Choroid | 1 | 2012 | 62 | 0.020 |
Why?
| | CpG Islands | 1 | 2012 | 152 | 0.020 |
Why?
| | Retinal Pigment Epithelium | 1 | 2012 | 69 | 0.020 |
Why?
| | Acetylation | 1 | 2012 | 246 | 0.020 |
Why?
| | Cell Hypoxia | 1 | 2012 | 235 | 0.020 |
Why?
| | Incidence | 1 | 2018 | 2644 | 0.020 |
Why?
| | Prospective Studies | 2 | 2015 | 7133 | 0.020 |
Why?
| | Exons | 1 | 2012 | 342 | 0.020 |
Why?
| | RNA Interference | 1 | 2012 | 448 | 0.020 |
Why?
| | Brain Neoplasms | 1 | 1999 | 1171 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2017 | 3381 | 0.020 |
Why?
| | Immune Tolerance | 1 | 2012 | 355 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2012 | 769 | 0.020 |
Why?
| | Transforming Growth Factor beta | 1 | 2012 | 457 | 0.020 |
Why?
| | Infant, Premature | 1 | 2013 | 541 | 0.020 |
Why?
| | Immunoglobulin G | 1 | 2013 | 847 | 0.020 |
Why?
| | Drug Design | 1 | 2009 | 156 | 0.020 |
Why?
| | Interleukin-1 | 1 | 2012 | 958 | 0.020 |
Why?
| | Gene Expression | 1 | 2013 | 1472 | 0.020 |
Why?
| | B-Lymphocytes | 1 | 2013 | 815 | 0.020 |
Why?
| | Colorado | 1 | 2018 | 4421 | 0.020 |
Why?
| | Mice, Congenic | 1 | 2007 | 22 | 0.020 |
Why?
| | Lung Neoplasms | 1 | 2001 | 2344 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2012 | 1698 | 0.020 |
Why?
| | Diet | 1 | 2015 | 1213 | 0.020 |
Why?
| | Histones | 1 | 2012 | 588 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2018 | 5066 | 0.020 |
Why?
| | Mice, SCID | 1 | 2007 | 351 | 0.020 |
Why?
| | Drug Delivery Systems | 1 | 2009 | 336 | 0.020 |
Why?
| | Organ Transplantation | 1 | 2009 | 228 | 0.020 |
Why?
| | Thymus Gland | 1 | 2007 | 306 | 0.020 |
Why?
| | Oxidative Stress | 1 | 2012 | 1269 | 0.020 |
Why?
| | Communication | 1 | 2011 | 846 | 0.010 |
Why?
| | Young Adult | 1 | 2018 | 12426 | 0.010 |
Why?
| | Killer Cells, Lymphokine-Activated | 1 | 1999 | 12 | 0.010 |
Why?
| | Adult | 1 | 2022 | 35576 | 0.010 |
Why?
| | Neoplasm Transplantation | 1 | 1999 | 257 | 0.010 |
Why?
| | Ouabain | 1 | 1998 | 18 | 0.010 |
Why?
| | Melanoma-Specific Antigens | 1 | 1998 | 5 | 0.010 |
Why?
| | Hybrid Cells | 1 | 1998 | 50 | 0.010 |
Why?
| | Middle Aged | 1 | 2017 | 31154 | 0.010 |
Why?
| | Ultraviolet Rays | 1 | 1998 | 383 | 0.010 |
Why?
| | Neoplasm Proteins | 1 | 1998 | 424 | 0.010 |
Why?
| | Drug Resistance, Neoplasm | 1 | 1998 | 759 | 0.010 |
Why?
| | Vaccination | 1 | 1998 | 1348 | 0.000 |
Why?
|
|
deZoeten's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|